During hepatic fibrogenesis, quiescent hepatic stellate cells (HSC) become active and transdifferentiate into myo-fibroblast-like cells. This process coincides with an increase in cell proliferation, loss of stored vitamin A droplets and excessive production and deposition of extracellular matrix (ECM) components. HSC activation is coupled with the sequential expression of cytokine receptors, including platelet-derived growth factor-beta receptor (PDGF-ßR). Although the underlying mechanisms remain incompletely understood, it is widely accepted that oxidative stress plays critical roles in activation of HSC during hepatic fibrogenesis. We have recently demonstrated that the antioxidant (-)-epigallocatechin gallate (EGCG), a major component in green tea extracts, significantly inhibited the proliferation of passaged HSC. The aim of the present study is to elucidate the underlying mechanisms. Since PDGF is a potent mitogen for HSC and mediates the early proliferative response, it was hypothesized that EGCG might inhibit HSC proliferation by interfering with the PDGF signal transduction. In this report, we demonstrated that EGCG, in two steps, significantly and effectively inhibited the proliferation of primary and passaged HSC. The polyphenolic compound initiated its inhibitory action by rapidly blocking the phosphorylation of tyrosines in PDGF-ßR elicited by PDGF in serum. This action was short-lived, persisting for a couple of hours. In addition, this antioxidant inhibited the gene expression of PDGF-ßR by blocking the activation of transcription factors AP-1 and NF-κB, which were required for the gene transcription. The latter action remained effective for no less than 48 hr. These results provided a novel insight into the mechanisms by which EGCG inhibits HSC growth. The inhibitory effect of the natural antioxidant, its long history of by guest on November 15, 2017
INTRODUCTION
Hepatic fibrosis occurs as a wound-healing process after many forms of chronic liver injury, including virus infection, auto-immune liver diseases and sustained alcohol abuse (1) . Hepatic stellate cells (HSC) are the most relevant cell type responsible for the excessive production and deposition of extracellular matrix (ECM) during the development of hepatic fibrosis. HSC are normally low mitotic ("quiescent") and mainly responsible for the uptake, storage, and delivery of retinoids. Upon liver injury, these cells become active and trans-differentiate into α-smooth muscle actin-positive myo-fibroblast-like cells. Several key phenotypic changes are accompanying the process, including an increase in cell proliferation, loss of stored vitamin A droplets, and excessive production and deposition of ECM components. Culturing quiescent HSC on plastic plates causes spontaneous activation leading to a myofibroblast-like phenotype, mimicking the process seen in vivo. This provides a simple model for studying mechanisms underlying the activation and trans-differentiation of these cells.
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creates binding sites for association of tyrosine-dependent proteins, such as Shc, Grb2, Src, etc (5), followed by activation of signal transduction pathways (6) . The tyrosine phosphorylation is, therefore, essential for activation of a series of intracellular signaling pathways that mediate changes in gene expression, cell migration, and cell proliferation (6) . Studies have indicated that during liver injury, the early proliferative response in HSC was mainly mediated by PDGF (7) . The onset of HSC proliferation coincides with the induction of the expression of PDGF-ßR, while PDGF-αR is not changed (8) .
Although the underlying mechanisms remain incompletely understood, accumulating evidence has indicated that oxidative stress plays critical roles in activation of HSC and hepatic fibrogenesis (9) (10) (11) .
Oxidative stress is formed by excessive production of reactive oxygen species (ROS), including hydrogen peroxide (H 2 O 2 ), which are generated endogenously by all aerobic cells as byproducts of a number of metabolic reactions (12) . Oxidative stress has been implicated in stimulating HSC entry into S-phase, NF-κB activation, and gene expression (9) . The antioxidant vitamin E shows its role in inhibiting the activation of HSC (9) , as well as in preventing iron-induced hepatic fibrogenesis (13) . However, the therapeutic efficacy of current well-known antioxidants, including superoxide dismutase, vitamin E and ascorbic acid, in treatment of human hepatic fibrosis is generally unimpressive (14) . Natural antioxidants, such as polyphenols from green tea extracts, have recently attracted considerable attention for prevention of oxidative stress-related diseases including cancers, cardiovascular diseases, and degenerative diseases (15, 16) . Green tea is the most consumed beverage in the world (17, 18) . Of the polyphenols purified from green tea, (-)-epigallocatechin gallate (EGCG) is a major constituent and the most potent antioxidant (19) . 7 maintained in DMEM supplemented with 10% FBS. Without a specific indication, activated HSC were used at the age of passage 4-8 in experiments. For some experiments, cells were serum-starved for 48 hr in DMEM with 0.4% FBS prior to the addition of 10% FBS and/or EGCG (99.5% purity, Sigma) for the indicated times. Pyrrolidine dithiocarbamate (PDTC), an inhibitor of NF-κB (26) , was purchased from Sigma. The process of serum-starvation of HSC is generally considered to render them "quiescent" (27, 28 ).
Determination of cell growth: Quiescent HSC were isolated from normal rats and incubated in DMEM containing 20% FBS. After 24 hr recovery, cells were treated with or without EGCG at the indicated concentrations for additional 6 days. Cell growth was determined by attached cell numbers counted by a cell counter (Coulter Corporation, Miami, FL). Cell proliferation was analyzed by 3 H-thymidine incorporation assays, as described previously (23) .
125 I-PDGF-BB Binding Assay: After 24 h recovery, freshly isolated quiescent HSC were treated with or without EGCG at the indicated concentrations for additional 6 days. Cells were washed once with binding buffer (25mM HEPES, pH 7.4, 125mM NaCl, 5mM KCl, 5mM MgSO 4 , and 1mM CaCl 2 ). Cells (10 4 ) were subsequently incubated with 125 I-PDGF-BB (Amersham) (1 to 50 ng/ml) in the binding buffer containing 0.2% bovine serum albumin (BSA) at 4ºC for 4 hr in the absence, or presence of a 50-fold excess of unlabeled PDGF-BB (CALBIOCHEM, San Diego, CA) to measure total, or non-specific binding, respectively. Cells were then washed at least three times with the binding buffer and lysed with 1% Triton X-100, 0.1% BSA, and 0.1M NaOH. The radioactivity of the aliquots of soluble fraction was 8 measured by a γ-counter. The difference in radioactivity between cells incubated with (i.e. non-specific binding) and without (i.e. total binding) excessive unlabeled PDGF-BB was considered as specific binding. Scatchard analysis of 125 -I-PDGF-BB specific binding data was used to evaluate the effect of EGCG on the affinity of receptors to PDGF-BB (29) .
Transient Transfection: Sixty-eighty percent confluent HSC in 6-well plastic plates were transiently transfected using the LipofectAMINE reagent (Life Technologies, Grand Island, NY). Each treatment or sample (3 µg DNA/well) was run in triplicate for every experiment. Experiments were repeated at least three times (n≥3). Luciferase assays were performed as previously described (25, 30) . Transfection efficiency was determined by co-transfection of a ß-galactosidase reporter, pSV-ß gal (0.5 µg DNA/well) (Promega).
Plasmid Constructs: The PDGF-ßR reporter plasmid pß12 was a gift from Dr. Keiko Funa (Ludwig Institute for Cancer Research, Uppsala, Sweden). In pß12, a fragment, containing 1366 base pair nucleotides upstream the start codon of mouse PDGF-ßR gene, was subcloned into a luciferase expression vector pGL2 (basic) (31) . Other PDGF-reporter plasmids with various sizes of the gene promoter region were derived from the parental pß12 generated by restriction enzyme digestion as indicated, or by PCR.
The expression plasmids of dominant negative JNK, the dominant negative c-Jun and the AP-1 reporter plasmid were previously described (24, 25) . Plasmids with site-directed mutations in either the AP-1 site or the NF-κB site, or in both sites, were derived from the plasmid pß12/T+E, by using GeneEditor™ in vitro
Site-Directed Mutagenesis System (Promega). The two bases CA at -693 and -692 in the AP-1 binding site 9 were mutated to TG, while the other two bases GG at -751 and -750 in the NF-κB binding site were mutated to AA. Site-directed mutations were confirmed by DNA sequencing. 
RNA isolation and
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RESULTS
EGCG inhibits primary HSC proliferation in vitro
We have previously demonstrated that EGCG significantly inhibited the proliferation of passaged HSC (23) . To further evaluate the effect of EGCG on primary HSC growth, HSC were isolated from normal rat livers. After recovery in DMEM with 20% FBS for 24 hr, the same number of cells were incubated in the media with or without EGCG at the indicated concentrations for additional 6 days. 
EGCG rapidly blocks the PDGF-initiated phosphorylation of tyrosines in PDGF-ßR
To test the hypothesis, studies were first focused on evaluating EGCG effects on phosphorylation of tyrosines in PDGF-ßR elicited by PDGF in serum. To reduce phosphorylated tyrosines in PDGF-ßR, passaged HSC were serum-starved in serum-free DMEM for 3 hr. Some of the cells were stimulated with exogenous PDGF-BB (20 ng/ml) for 1 hr as a positive control. The others were stimulated with 10% FBS, with or without neutralizing anti-PDGF antibodies, in the presence or absence of EGCG either at different concentrations for a fixed time (1 hr) ( Fig. 2A ), or at a fixed dose (50µM) for different hours ( 
EGCG inhibits the expression of PDGF-ßR in both primary and passaged HSC
As demonstrated earlier, the effect of EGCG on blocking the phosphorylation of tyrosines in PDGF-ßR was only sustained for less than 5 hr (Fig. 2B) , while the effect of EGCG on inhibiting cell proliferation lasted for days in primary HSC (Fig. 1A ) and in passaged HSC (23) . It was, therefore, assumed that in addition to the rapid, short-life effect, EGCG should have additional, long-life effects on inhibiting HSC proliferation, including reducing the gene expression of PDGF-ßR.
Primary HSC were treated with or without EGCG at the indicated concentrations starting at day 2 until day 7. Cells (10 4 ) were subsequently incubated with 125 I-PDGF-BB (1 to 50ng/ml) at 4ºC for 4 hr in the absence, or presence of a 50-fold excess of unlabeled PDGF-BB to measure total, or non-specific binding, respectively. Specific binding curves were obtained by subtraction of non-specific binding from total binding (Fig. 3A) . The results indicated that EGCG caused a dose-dependent reduction in specific binding of 125 I-PDGF-BB to primary HSC. Scatchard analyses of these data indicated that EGCG did not alter the binding affinity of receptor(s) to PDGF-BB (data not shown). These results collectively suggested that EGCG might reduce the level of membrane PDGF-ßR in primary cells. RNase protection assays 15 (RPA) were used for further analyses of EGCG effects on PDGF-ßR mRNA in primary HSC (Fig. 3B ).
After recovery for 24 hr, freshly isolated primary HSC were incubated for other 3 days. A part of the cells were then harvested (Day 4). The rest part of the cells started the treatment with or without EGCG at the indicated concentrations for additional 3 days (Day 7). As shown in Fig. 3B by RPA, compared with cells aged at day 4 (Day 4), primary HSC aged at day 7 (Day 7) acquired a higher level of PDGF-ßR mRNA, which was inhibited by EGCG in a dose-dependent manner. 28S rRNA was used as an internal control for equal loading. Similar results were obtained from serum-starved passaged HSC (Fig. 4) . The process of serum-starvation of HSC is generally considered to render them "quiescent" (27, 28) . Serum stimulation significantly increased the abundance of steady state levels of PDGF-ßR mRNA demonstrated by realtime PCR (Fig, 4A & B) . EGCG, in dose-dependent ( Fig. 4A ) and time-dependent manners ( Fig. 4B ), reduced the levels of PDGF-ßR mRNA in passaged HSC. Further IP and immuno-blotting analyses confirmed the EGCG inhibitory effect on the protein expression of PDGF-ßR in activated passaged HSC (Fig. 4C ). Taken together, these results demonstrated that EGCG significantly inhibited the serum-induced expression of PDGF-ßR in both primary and passaged HSC in dose-and time-dependent manners, which lasted for no less than 48hr.
EGCG reduces the mRNA stability and the gene promoter activity of PDGF-ßR
To begin exploring the mechanisms by which EGCG inhibited the expression of PDGF-ßR in HSC,
we evaluated the effect of EGCG on PDGF-ßR mRNA stability, and on the gene promoter activity of the receptor. Serum-starved HSC were stimulated with 10% FBS for 24 hr to induce the expression of 16 PDGF-ßR. Cells were subsequently treated with actinomycin D (10µg/ml) alone, a transcriptional inhibitor, or together with EGCG (50µM) for the indicated hours. Total RNA was isolated from the cells.
The abundance of PDGF-ßR mRNA and 28S rRNA, as an internal control, was analyzed by RNase protection assay (RPA) (Fig. 5A ). As analyzed in Fig. 5B , the data from RPA (n=3) revealed that the serum-induced PDGF-ßR mRNA had a half-life longer than 6 hr. EGCG significantly reduced its half-life to less than 4 hr ( 
EGCG inhibits AP-1 and NF-κ κ κ κB activities in HSC
To further explore the mechanisms by which EGCG inhibited the expression of PDGF-ßR gene in HSC, we studied effects of EGCG on AP-1 and NF-κB activities. As shown in Fig. 8A , EGCG caused a dose-dependent reduction in phosphorylated JNK while no changes in total JNK, indicating that EGCG inhibited serum-induced JNK activation. Electrophoretic mobility shift assays (EMSA) ( 
DISCUSSION
We have reported that EGCG significantly inhibited the growth of passaged HSC (23), as well as primary HSC (Fig. 1) . The underlying mechanisms remain largely unknown. In this communication, our studies demonstrated that EGCG promptly inhibited the phosphorylation of tyrosines in PDGF-ßR elicited by PDGF in serum, which only lasted for a couple of hours. In addition, this antioxidant blocked the activation of AP-1 and NF-κB, which, in turn, resulted in a marked reduction in the promoter activity of PDGF-ßR gene and led to inhibition of PDGF-ß gene expression. The latter action persisted for no less than 48 hr. The combination of these two actions permitted EGCG to interfere with PDGF signaling, thus efficiently exerting its biological function in inhibiting the proliferation of primary and passaged HSC.
EGCG has been previously found to have no detectable toxicity in activated HSC in vitro at a concentration up to 100µM, based on no detectable lactate dehydrogenase release, and a rapid recovery of
HSC proliferation after withdrawal of EGCG (23).
PDGF is a potent mitogen for HSC proliferation in vitro and in vivo. The onset of quiescent HSC proliferation coincides with an increase in the expression of PDGF-ßR with no change in PDGF-αR (8) .
Tyrosine Phosphorylation in PDGF-ßR serves as a critical link between extracellular PDGF stimulation and intracellular signaling. Our results showed that EGCG, in less than 30 min, blocked the phosphorylation of tyrosines in PDGF-ßR elicited by PDGF in serum (Fig. 2) . This action instantly disassociated tyrosine-dependent proteins, such as Src, with PDGF-ßR and blocked PDGF signaling to downstream elements in activated HSC ( Fig. 2A) . Several other studies reported the effect of EGCG on inhibition of tyrosine phosphorylation (33, 34) . The mechanisms by which EGCG inhibits the phosphorylation of tyrosines in PDGF-ßR remain poorly understood. Previous studies indicated that EGCG inhibited the expression of tyrosine kinase gene in lung cancer cells (35) . It is also possible that EGCG directly acts as a tyrosine kinase inhibitor. Additional experiments, beyond the scope of this report, are necessary to clarify the underlying mechanisms of the EGCG action.
In addition to the instant, short-life action, EGCG also exerted its long-lasting action to block PDGF signaling by reducing the gene expression of PDGF-ßR in cultured HSC (Fig. 3-5 ). EGCG not only accelerated the maturation and degradation of PDGF-ßR mRNA (i.e. a reduction in half-life) (Fig. 5 ), but also inhibited the activation of the gene promoter ( Fig. 6 & 7) , by reducing AP-1 and NF-κB activities ( Fig. 8 & 9 ). Both transcription factors were required and played critical roles in regulating the promoter activity of PDGF-ßR gene in activated HSC (Fig. 6 & 7) . We have previously shown that EGCG inhibited NF-κB activity induced by acetaldehyde in activated HSC (23) . Other studies have shown that the antiandrogen action of EGCG was mediated by repressing the transcription of androgen receptor gene and by inhibiting SP-1 activity in prostate cancer cells (36) . In addition, previous studies have demonstrated that EGCG down-regulated TNF-α gene expression by blocking NF-κB activation in a macrophage cell line (37) .
Although the causal relationship remains unclear, NF-κB activation was observed closely associated with HSC activation and survival (9, 38, 39) . We demonstrated that EGCG reduced NF-κB DNA binding activity to the PDGF-ßR promoter and inhibited its trans-activating ability (Fig. 9 ), leading to a significant 22 reduction in the expression of PDGF-ßR gene in cultured HSC. The inhibitory effect of EGCG on NF-κB activity was also previously observed in other cell types (22, 40) . A recent study further indicated that EGCG inhibited IKK activity and that the polyphenol was the most potent IKK inhibitor among green tea extracts (41) . In addition, a recent study evaluated effects of EGCG on the expression of 588 genes in human lung cancer cell line by cDNA microarray (35) . EGCG significantly down-regulated four genes.
Among them were NF-κB inducing kinase (NIK) and tyrosine-protein kinase. Inhibition of NIK/IKK signaling complex resulted in the suppression of NF-κB activation. These results are consistent with our observations in this communication.
Oxidative stress has been implicated in the pathogenesis of a variety of human diseases, including hepatic fibrogenesis (42) . Previous experimental results have suggested that relaxing oxidative stress by antioxidants, including vitamin E, might be an effective therapeutic strategy for treatment and prevention of hepatic fibrogenesis (9, 13) . However, the therapeutic efficacy of current well-known antioxidants in treatment of human hepatic fibrosis is generally unimpressive (14) . The antioxidant potential of EGCG is far greater than that of vitamin E and/or C (20) , which might allow it to succeed where other antioxidants have failed in preventing oxidative stress-related diseases. Consumption of green tea has been linked to a lower incidence of certain cancers and diseases in humans (19, 43) . This polyphenol was previously shown not to harm the liver and kidney in vivo (43) . Its potent antioxidant capability and long history of beverage consumption without adverse health effects make it a possible alternative to vitamin E for therapeutic treatment of hepatic fibrosis. Total PDGF-ßR, as a control for equal loading, was detected by anti-PDGF-ßR antibodies (α-PDGF-ßR).
Representatives of three independent Western blotting analyses are shown here. 
